Nektar Therapeutics: Top Gainer from S&P 500 in 1Q18
Last month, Nektar Therapeutics (NKTR) stock rose 25.7%, from $84.55 on March 1, 2018, to $106.26 on March 29, 2018. According to reports, Nektar Therapeutics has risen 78%, proving to be the best-performing stock in the S&P 500 in 1Q18. Since November 2017, the company has been on an upward trajectory, mainly due to positive results from the dose-escalation phase of the PIVOT-02 Phase 1/2 expansion study designed to evaluate the efficacy and safety of Nektar Therapeutics’ NKTR-214 in combination with Bristol-Myers Squibb’s (BMY) Opdivo in patients suffering with non-small cell lung cancer, renal cell carcinoma, and stage 4 melanoma.